$VRDN

8 months ago (Last updated: 1 month ago)

Grafico trading Forex con analisi di volatilità e trend di mercato, piattaforma Merlintrader Trading Pub.

Grafico di trading Forex con analisi tecnica, strumenti di trend, volatilità e indicatori, utilizzato nel Merlintrader Trading Pub.

Grafico azionario con tendenze e indicatori — $VRDN 3

Grafico è interessante, bel canale rialzista. Incamminata verso i suoi catalyst; non male se si riesce a prendere alla base del canale. Ha pochi volumi giornalieri il chè non mi piace tanto. Cmq interessante.

Viridian Therapeutics (VRDN) — Merlintrader Report

Viridian Therapeutics (VRDN) — Company & Catalyst Report

Updated: October 2025 — Merlintrader Biotech Coverage

Overview

Viridian Therapeutics (NASDAQ: VRDN) è una biotech late-stage focalizzata su anticorpi per patologie autoimmuni ed endocrine rare. Il candidato principale, veligrotug (VRDN-001), indirizza IGF-1R per la Thyroid Eye Disease (TED), in competizione con Tepezza. La pipeline include VRDN-003 (formulazione sottocutanea), VRDN-006 (next-gen STAT3 inhibitor con lettura proof-of-concept attesa entro fine 2025) e VRDN-008 in fase di scoperta.

Upcoming Catalysts (Estimated)

Fine 2025: Lettura proof-of-concept per VRDN-006 in volontari sani.
Novembre 2025: Sottomissione BLA per veligrotug (VRDN-001) in TED.
Dicembre 2025: Prevista sottomissione IND per VRDN-008.

Financial Position

Al Q2 2025, cassa e equivalenti ~$310 M, con runway stimata fino a metà 2026. Le risorse sono focalizzate sui programmi TED late-stage e sulla piattaforma STAT3 early-stage.

Merlintrader Comment

VRDN resta un mid-cap chiave tra immunologia e oftalmologia. Il calendario catalyst nei prossimi mesi è solido: BLA di VRDN-001 e prime evidenze umane per VRDN-006. Probabile rafforzamento del sentiment man mano che si avvicina la lettura di fine 2025, con potenziale per setup di momentum pre-catalyst.

Nota: date stimate a scopo operativo; verificare gli aggiornamenti nelle comunicazioni IR ufficiali.

1 thought on “$VRDN”

Merlintrader says:
10/13/2025 at 2:20 PM
Grafico è interessante, bel canale rialzista. Incamminata verso i suoi catalyst; non male se si riesce a prendere alla base del canale. Ha pochi volumi giornalieri il chè non mi piace tanto. Cmq interessante.

Comments are closed.

Welcome to Merlintrader!
Here we share ideas, analysis and news from the biotech and small-cap world, with a special focus on the catalysts that really move the market.
If you like the content on this site, please help me by sharing it on social media and in other forums. Thank you!

✦ Disclaimer: The information provided is strictly for educational and informational purposes. This content represents independent, informational research and does not constitute regulated investment research or financial advice. I am not a licensed financial advisor or an authorized investment professional. Nothing here should be interpreted as a recommendation to buy, sell, or trade any security. If you need personalized financial advice, you should consult a qualified and authorized professional. Biotech and small-cap stocks carry significant risk, including the potential loss of all invested capital. Each user remains fully responsible for their own trading decisions. Full legal disclaimers.

✦ RunUP Biotech: Interested in understanding market dynamics around FDA catalysts and clinical trials? The RunUP Biotech strategy provides a framework for analyzing pre-event positioning, volume patterns, and risk-management approaches. Educational focus on probability and pattern structure — not predictions or guaranteed outcomes. Learn more →

✦ Support Merlintrader: This website is free and has no paywall. If you find the reports and tools useful, you can support the project via Buy Me a Coffee — it helps me cover costs and keep publishing independent analysis.

✦ Disclosure: I closed my DRTS position today, May 11, at $10.29 per share, after entering at $7.31 per share. I opened a small position in CING on May 12 at $4.90 per share. Read the full disclaimer.

```

Free research library

Explore the Merlintrader blog

Inside the site you will find hundreds of free reports, deep dives on biotech and small caps, FDA catalyst coverage, market analysis, and articles built to help readers understand what really moves these stocks.

Full reports on individual stocks
FDA, catalyst and clinical-trial analysis
Daily briefings, watchlists and market themes
A free archive updated on a regular basis

Explore the blog

Free content, readable structure, and regular updates.

Archivio gratuito

Esplora il blog Merlintrader

Nel sito trovi centinaia di report gratuiti, approfondimenti su biotech e small cap, catalyst FDA, analisi di mercato e articoli pensati per aiutare i lettori a capire meglio cosa muove davvero questi titoli.

Report completi su singoli titoli
Analisi di catalyst, FDA e trial clinici
Daily briefing, watchlist e temi di mercato
Un archivio gratuito aggiornato con regolarità

Vai al blog

Contenuti gratuiti, struttura leggibile e aggiornamenti costanti.

Scanner for active traders

Try ChartsWatcher free, then unlock 10% OFF with SAVE10

ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.

Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.

Start free – then use SAVE10

No credit card required to start. Apply SAVE10 when upgrading.

Recommended platform

One platform. All your brokers.

Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.

A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.

Get 1 Month Free ➔

Multi-broker workflow + customizable layouts in one platform.

Authors: Merlintrader, Jane and Gemini

Author's note

In every piece of content I share things as I personally interpret them, based on raw data from official company filings, regulatory documents, conference call transcripts and other primary sources where available. Some parts of the research and structure are supported by AI assistants (Jane and Gemini), which help me organise data, cross-check details and improve charts or visuals. However, any interpretation, opinion and final judgement remain entirely my own as a trader like you, not as a licensed financial advisor or registered analyst. Market sentiment can change quickly, while official documents and numbers remain what they are. It is also possible for me to make mistakes: collecting and cross-checking FDA timelines, clinical data, filings and corporate updates is complex, so inaccuracies may occur. If you spot something that looks off, feel free to let me know and I will correct it. Please do not treat this content as professional investment advice, but as one more piece of information to compare with your own research and the opinion of qualified professionals.

If you find these reports useful and want to support the project, you can make a voluntary one-time donation via PayPal or Buy Me a Coffee. It helps cover data, tools and hosting costs so that the content can remain independent and freely accessible.

Tools and research platforms used by Merlintrader

Below is a shortlist of tools and platforms that I personally use to follow prices, catalysts, fundamentals and sentiment. Links are provided for transparency and convenience only.

Finviz Elite – advanced stock screener and charting, used for heatmaps, relative performance and technical context.
ChartsWatcher – real-time, next-generation scanner for the US stock market. Used to monitor intraday momentum, volume spikes and colour-coded pattern alerts.
Stocktwits – social stream focused on tickers, used only as a sentiment and activity indicator, not as a source of investment recommendations.
Monica.im – AI assistant used for light reports, drafting and quick research; helps with structuring notes and first-pass analysis alongside the deep-dive work published on Merlintrader.
Medved Trader – professional trading and charting platform used for real-time execution, order-flow and detailed intraday analysis. No affiliate link; mentioned because it is part of the actual trading workflow.
Merlintrader trading Blog – the home for biotech-focused reports, dashboards and educational articles that expand on the ideas mentioned in this document.

AI usage disclosure

Content on Merlintrader may be prepared using a human + AI workflow. Drafting, editing and data organisation may be supported by generative AI tools, for example large language models provided by third-party vendors, based on prompts and instructions defined by the author. All sources are publicly available, and the final selection of data, checks, opinions and conclusions is carried out by the author, who remains fully responsible for the content.

Find out how I use AI on Merlintrader: AI, retail and Merlintrader

Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.

Legal disclaimer – please read carefully

Each piece of content is provided strictly for informational and educational purposes. It is not and must not be interpreted as investment advice, investment research in a regulatory sense, portfolio management, or a recommendation to buy or sell any security or financial instrument. The author is not a licensed investment advisor, not a registered broker, and not a FINRA/SEC-registered analyst or portfolio manager. Any reference to potential scenarios, price levels or catalysts is purely illustrative and reflects a personal, non-professional view based on publicly available information at the time of writing.

Nothing in any content published on Merlintrader should be considered a solicitation to the public to invest, nor an invitation to raise capital, nor a promise of profit or of capital protection. Biotech and healthcare stocks in particular can be highly volatile and speculative, especially around clinical and regulatory catalysts. Before making any investment or trading decision, always perform your own due diligence and consider consulting a qualified, regulated financial professional who can evaluate your personal situation, objectives and risk tolerance. Past performance and historical examples do not guarantee future results.

The author may hold, or may have held, long or short positions in some of the securities mentioned in Merlintrader content, and may open, close or modify such positions without notice. This potential alignment of interests may influence the tone or focus of the analysis. No position held by the author changes the fact that this content is not investment advice and should not be used as such.

Biotech Catalyst Calendar

For a broader, continuously updated view of upcoming biotech catalysts (PDUFA dates, major clinical readouts, regulatory events and key conferences), you can consult the dedicated calendar on Merlintrader.

Open the Biotech Catalyst Calendar

1 thought on “$VRDN”

Related Stories

3 Biotech Stocks Facing Near-Term FDA Catalysts: MannKind ($MNKD), Viridian Therapeutics ($VRDN) and Vera Therapeutics ($VERA)

Viridian Therapeutics (VRDN): after the crash, what still matters now?

Viridian Therapeutics ( $VRDN ): why the stock crashed on “positive” REVEAL-1 data

VRDN Viridian Therapeutics Inc

ONCY Oncolytics Biotech, Inc

VNDA Vanda Pharmaceuticals Inc

You May Have Missed

Neumora Therapeutics (Nasdaq: $NMRA): Navacaprant Is Over, the Platform Story Moves to NMRA-511, NMRA-898 and NMRA-215

Amylyx Pharmaceuticals (Nasdaq: $AMLX) — Avexitide, Post-Bariatric Hypoglycemia and the LUCIDITY Phase 3 Trial

The Week Ahead: Fed Pressure, Trump Risk, SpaceX Aftershock and Small-Cap Catalysts to Watch — $SPRO $RKLB $PL

Short Squeeze Watch: three crowded short-interest stocks, but not the same setup

Try ChartsWatcher free, then unlock 10% OFF with SAVE10